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Abstract
Advocates of “personalized” genomic medicine maintain that it is revolutionary not just in what it
can reveal to us, but in how it will enable us to take control of our health. But we should not
assume that patient empowerment always yields positive outcomes. To assess the social impact of
personalized medicine, we must anticipate how the virtue might go awry in practice.
Human genome research owes a debt of gratitude to the historian of science Thomas Kuhn,
who introduced the idea that conceptual change in science can happen through “paradigm
shifts” that go beyond incremental problem-solving.1 While Kuhn was agnostic about
whether such revolutions necessarily constitute “progress,” the popular understanding has
become that paradigm shifts are the most effective form of scientific progress. As a result,
appealing to the prospect of a “paradigm shift” for biomedical science has been successful in
generating public and private investment in genomics research, and a wide variety of
stakeholders promote its translational goals as a new paradigm for medicine, under the
banner of “personalized genomic medicine.”2 As Francis Collins, long-time leader of human
genomics research in the United States, puts it:
We are on the leading edge of a true revolution in medicine, one that promises to
transform the traditional “one size fits all” approach into a much more powerful
strategy that considers each individual as unique and as having special
characteristics that should guide an approach to staying healthy. … If you are
interested in living life to the fullest, it is time to harness your double helix for
health and learn what this paradigm shift is all about.3
A decade after the completion of the Human Genome Project, the widespread appeal of
personalized genomic medicine’s vision and potential virtues for health care remains
compelling. Advocates argue that our current medical regime “is in crisis as it is expensive,
reactive, inefficient, and focused largely on one size fits all treatments for events of late
stage disease.”4 What is revolutionary about this kind of medicine, its advocates maintain, is
that it promises to resolve that crisis by simultaneously increasing the ability to be
“personalized,” “predictive,” “preventive,” and “participatory.” Some call personalized
genomic medicine “P4 Medicine,” inscribing these cardinal virtues into the movement’s
name.5
All of these putative virtues have interesting implications for the future of health care. In this
essay, we are especially interested in the claims that personalized medicine will lead to a
more “participatory” or “patientcentered” approach to health care, in which patients are
“empowered” to take more personal control over their care. The rhetoric of patient
empowerment is nothing new in health care, but personalized medicine is an interesting case
study because it portrays empowerment as one of its key virtues and as a mechanism for
fixing the health care “crisis.”
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Who Emphasizes “Patient Empowerment”
Personalized genomic medicine is the product of many minds and has many interpretations.
A close reading of the literature yields at least three concentrations of stakeholders who are
heavily invested in empowerment rhetoric:6 (1) direct-to-consumer genomic scanning
companies and the “early adopters” of their services; (2) the leaders of genomic medicine
programs at premier biomedical research and health care institutions; and (3) genomic
medicine’s government sponsors and advocacy groups.
Direct-to-consumer companies and early adopters
It is no surprise that the theme of patient empowerment is invoked in the marketing of
companies that sell genetic testing and genome scanning directly to consumers and in the
enthusiastic writings of their customers. Capitalizing on the “open-source” ethos of the
Internet, these companies solicit business online with marketing rhetoric that echoes the
postmodern suspicion of authority and paternalistic expertise. As the company 23 and Me
explains, “We believe that your genetic information should be controlled by you.”7 In this
context, claims that, for example, “getting to know your personal genome will empower you
and provide you with a road map to improve your health” are ubiquitous.8 This appeal also
clearly resonates with the early adopters—those who use and blog about these services—
whose reported reasons mirror the empowerment rhetoric of the companies’ marketing
materials.9
Appeals to increased personal control are not unusual in a marketplace environment. We
expect companies to exaggerate claims as they market their products. What is interesting is
that the claims made by the “consumer genomics” industry and their customers do not stray
far from mainstream biomedical rhetoric about personalized genomic medicine. The public
might not expect academic institutions—especially those that operate on public financial
support—to engage in the same kind of marketing strategies as private industry.
Premier research and health care institutions
Translational genomic research programs such as the Institute for Systems Biology and the
Coriell Institute for Medical Research often espouse patient empowerment as one of the
goals of their research.10 At the P4 Medicine Institute, the “passive patient will be
transformed into the engaged consumer who takes ownership of his or her own health.
Healthcare will become enjoyable, actionable, and effective”—or so its Facebook page
claims.11 Prominent hospital-based programs like the Duke Center for Personalized
Medicine and the Center for Personalized Healthcare at the Cleveland Clinic also stress that
their mission is to “empower patients to understand their unique health needs and access
resources that will help them achieve optimal health,”12 or to “empower patients to actively
participate in their healthcare.”13
This is not traditional rhetoric for premier medical institutions, which have a financial
interest in reinforcing their special expertise and have in the past favored more paternalistic,
care-centered marketing.14 It is, however, consistent with a contemporary refrain about
social policy in the United States, including health insurance, which emphasizes personal
responsibility and self-reliance over reliance on the government or other services.15
Government sponsors and advocacy groups
Personalized genomic medicine’s empowering potential has also been embraced in federal
policy. Empowerment rhetoric appears in its promotion as the primary “translational” goal
of the genomic research sponsored by the National Institutes of Health,16 and former Health
and Human Services Secretary Michael O. Leavitt made the Personalized Health Care
Juengst et al. Page 2













Initiative a priority initiative of the Department of Health and Human Services.17 Supporting
these efforts is the leading advocacy group for the advancement of personalized medicine—
the Personalized Medicine Coalition, which promotes personalized medicine as “proactive
and participatory, engaging patients in lifestyle choices and active health maintenance to
compensate for genetic susceptibilities.”18
In sum, although their other interests vary, actors across influential stakeholder groups in
personalized medicine concur that patient empowerment is a primary virtue of the
“paradigm shift” they espouse. As one review concludes:
The main characteristic of the evolving health care delivery model is that it is
starting to become more collaborative; moving to a co-diagnosis, co-care model
between physicians, patients and other parties. The physician could start to be seen
as a colleague and advisor, as one of many input sources in fashioning a care plan.
The patient could become more of an informed participant, an active responsibility-
taker, the owner, administrator, and coordinator of his or her health program and
health data.19
Whatever rationales link this virtue to the genomic technologies underpinning personalized
medicine, this widespread support may raise the profile of efforts to empower patients as the
personalized approach to medicine is implemented. Efforts to empower patients must be
attempted with care, however, because social scientific research has already shown that
patient empowerment practices have a double-edged quality that sometimes cuts against
society’s health care interests.
Empowerment as a Double-Edged Virtue
Supporting the patient’s voice in clinical encounters has been the hallmark of medical ethics
and the “patients’ rights” movement in health care law since the 1970s.20 Within genomic
research, discussions of the active, empowered patient have often centered on early adopters
of technology as “lay experts” in a “genetic citizenry” who may actually help construct and
advance the technology.21 But studies of that movement show that the virtue of patient
empowerment has a correlative vice—the relocation of responsibility for health care away
from social and political realms and onto the shoulders of patients. This shift has long been
signaled in the writings of medical sociologists and bioethicists, who have warned that “the
emphasis on individual empowerment often disguises the fact that personal genomics is
pushing the individualization of responsibility for health one step further.”22
The shift should prompt concern within the personalized genomic medicine movement
because it may increase pressure on patients to comply with physicians’ recommendations.
Even more worrisome is that individuals who are unable to become “health-creating
persons” or who do not make the “right” health choices are easily “marked out as
irresponsible and hence unfit to be self-governing citizens.”23 These problems become
increasingly complicated when the supposed source of the condition is understood to be
genetic.
We should not assume that patient empowerment always yields positive outcomes. To assess
the social impact of personalized medicine, we must anticipate how this virtue might go
awry in practice. To prevent health care responsibilities from shifting in counterproductive
ways for both clinicians and patients, those promoting personalized medicine must be clear
about what goals their appeals to empowerment are meant to achieve, and consumers must
weigh the relative value of these goals against their own interests. As a starting point, the
promoters could provide evidence of the extent to which genetic information brings
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actionable intelligence for patients. If the information given to patients has no effect on their
actions, then the promise of patient empowerment is empty.
The Contingency of Empowerment
Most of the virtues ascribed to personalized genomic medicine flow from the fact that
genomic tools focus attention on the role of genetic factors in health and disease. Genomic
medicine is “personalized” because it aims to tailor health care interventions to the
individual patient’s unique constellation of genetic factors. It is “predictive” because it uses
genome-wide genetic associations to assess future health risks, and it is “preventive” if those
genomic risk assessments can lead to prophylactic interventions that allow predicted
problems to be avoided or forestalled.
But how does the link between genomic medicine and patient empowerment come about? It
is difficult to see how patient empowerment necessarily and simply flows from genomic
science and technology. Genomic science can provide two kinds of information relevant to
health care decisions: (1) pharmacogenomic information about a patient’s chances of
responding well or poorly to a therapeutic regimen, and (2) genomic susceptibility
information about a patient’s chances of resisting or succumbing to other environmental or
degenerative health threats. Neither kind of information obviously has a role in empowering
patients that is analogous to its role in understanding, preventing, or treating disease.
Pharmacogenomic information
A patient and a physician might use pharmacogenomic information to make more informed
choices about alternative treatment regimens, but there is nothing about this information that
inherently shifts the nature of the patient’s relationship with the physician or increases the
patient’s ability to control the choice between treatments. Pharmacogenomics decision-
making still takes place within the traditional fiduciary paradigm in which patients either
reject or, more likely, accept professional recommendations.
In fact, because genomic medicine generates more risk information and makes that
information the key lens for approaching health and disease, patients may actually find that
they have less ability to influence health care decisions and treatments. When the relative
risks and benefits of treatment choices are uncertain, patients’ preferences about how to
gamble are given significant weight. If molecular profiling can help clarify treatment
tradeoffs, however, physicians will be able to give their patients “doctor’s orders” more
confidently and with more authority.
Many programs seem to acknowledge this by framing the “personalization” of genomic
medicine as “allowing healthcare professionals to customize your treatment for what works
best for you” so that “your physician can treat you with greater precision, fewer side effects
and with better results.”24 According to the American Medical Association, “genetic testing,
except under the most limited circumstances, should be carried out under the personal
supervision of a qualified health care professional” because “without the guidance of a
physician, genetic counselor, or other genetics specialist, test results could be misinterpreted,
risks miscalculated, and incorrect health and lifestyle changes pursued.”25
Pharmacogenomic information is blind to psychosocial or cultural considerations that might
result in different definitions of “responding well” and “responding poorly” for patients and
their physicians, and there is little research on the possible influence of cultural factors on
pharmacotherapeutic responses.26
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In contrast, genomic susceptibility testing carries greater potential to disrupt the traditional
therapeutic relationship between patients and physicians. Because its predicted health risks
and prospects for prevention are largely matters of diet, lifestyle, and occupational and
environmental exposure, genomic medicine takes some of the decision-making out of the
hands of physicians and puts it into both the hands of patients and of the social institutions
that regulate these other dimensions of life. To the extent that those institutions are less
paternalistic than traditional medicine, this shared responsibility should expand the ability of
patients to affect their health decisions. It is, therefore, not surprising that the attention of
medical stakeholders is drawn to pharmacogenomics, while the attention of users and
providers of “consumer genomics” is instead drawn to genomic susceptibility testing.
Ironically, however, the risk information provided by genomic susceptibility testing rarely,
if ever, remains at the individual level. Instead, it is usually mapped onto group-level
experiences and measurements. The first page of a report by the 2008 President’s Council of
Advisors on Science and Technology makes this point clear:
“Personalized medicine” refers to the tailoring of medical treatment to the
individual characteristics of each patient. It does not literally mean the creation of
drugs or medical devices that are unique to a patient, but rather the ability to
classify individuals into subpopulations that differ in their susceptibility to a
particular disease or their response to a specific treatment. Preventive or therapeutic
interventions can then be concentrated on those who will benefit, sparing expense
and side effects for those who will not.27
Because of its statistical foundation, genomic information can only illuminate the health
risks of genetic superfamilies, and the best genomic medicine can do is classify individuals
as members of those families. It will be a long time before individualized treatment is a
routine part of disease management. As a result, some argue that what is often referred to as
“personalized medicine” should more accurately be described as “stratified medicine.”28
Of course, it would be a major rhetorical retreat for genomic medicine to give up the idea of
individualized assessments and “tailored” treatments in favor of stratifying patients into
categories that are, ironically, not so far from a one-size-fits-all approach in the end. Most
promoters of genomic medicine therefore express hope that the present state is a stop-gap
stage. As Francis Collins writes:
The goal for personalized medicine must be to move as swiftly as possible toward
the identification of individual risk factors, be they environmental or genetic, that
play a direct role in disease risk. Racial profiling in medicine, even if well
intentioned right now, should recede into the past as a murky, inaccurate, and
potentially prejudicial surrogate for the real thing.29
This hope for greater personalization has to be an article of faith for promoters of genomic
medicine, in part because the general prospects of individual and community empowerment
in the United States are so intimately affected by population stratification. As Collins
suggests, against the backdrop of social and political stratification, population classification
schemes based on racial and ethnic categories can be actively disempowering for
individuals, by encouraging potentially prejudicial associations between their group
affiliations and health care risks.
Why Emphasize Patient Empowerment?
Patient empowerment is not a particularly revolutionary idea, nor is it unalloyed as a virtue,
given the responsibilities it invokes. It has no clear source in genomic tools, and, indeed,
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these tools may even undermine patient empowerment in the context of traditional clinical
relationships between physicians and patients. Outside the clinical setting, too, the potential
sources of patient empowerment would seem to collapse into the ambiguous benefit of being
simply classified into a social group with known health risks. Why, then, is patient
empowerment emphasized by personalized genomic medicine’s proponents as a cardinal
virtue of the paradigm? The literature suggests at least three possible rationales: (1) that
patient empowerment makes a virtue of clinical necessity because much of the preventive
promise of genomic medicine depends on individual patient lifestyle and behavior
modification; (2) that it imports a free-standing moral concern against medical paternalism,
fueled by the marketing interests of the “consumer genomics” industry; and (3) that it
exploits the appeal of enhanced patient autonomy in order to generate political and public
support for the paradigm. The literature provides enough illustrations of each to make them
all merit further study.
A virtue of necessity?
In her study of personalized genomic medicine, Alison Harvey quotes an early user’s telling
testimonial about its empowering capacity:
Since being given the results of my test, my initial feelings of fear and depression
have gradually been replaced by a sense of empowerment. … “There is no need to
worry, providing you change your life-style,” [the doctor] kept repeating. So that is
what I have decided to do. I now have the greatest possible incentive to change my
way of life.30
On the one hand, it is positive that this patient came away with a sense of empowerment and
managed to overcome his initial fear and depression. On the other hand, the doctor’s
repeated emphasis on general lifestyle change may have been offered only in the absence of
more meaningful or specific advice. But by styling participation as an expansion of patient
control, the concept of empowerment allows for the creation of complementary obligations
on the patient’s part. As patients make more “responsible” choices, they will also have and
perceive positive results, which further reinforce those choices. Of course, this also increases
the risk that personalized genomic medicine might go awry in ways that other responsibility-
inducing empowerment efforts have in the past, which should put us on alert for any
unintended consequences of empowerment.
A moral stand against paternalism?
A second possible source of personalized genomic medicine’s commitment to patient
empowerment is a moral rejection of medical paternalism. This rejection taps a longstanding
social conversation about the need for shared decision-making in medicine, fueled by a
growing concern over medical error and the demise of the traditional sick role. As
skepticism about physicians’ abilities to interpret genomic information grows, so does
public interest in gaining access to that information directly. As one personalized medicine
advocate writes:
Designating physicians as gatekeepers for genetic information isn’t just
disempowering—it’s basically sticking healthcare in a time capsule for a decade or
more, until physicians get up to speed. … This persistent paternalistic streak also
reflects a lack of faith in the ever-more empowered patient, who is eagerly scouring
the Internet for the latest research concerning her condition.31
Once again, of course, this rationale will be most attractive to stakeholders outside the
traditional clinical setting, such as the direct-to-consumer genetic testing companies and the
consumers who use their services. One common justification for marketing genomic
services to consumers is the hope that a “greater sense of individual ownership of personal
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genomic information could replace overly complex and paternalistic institutional proxies for
the protection of personal genotype and sequence data, and also could encourage research
participants and patients to become better educated regarding genetic contributors to
disease.”32 For health policy purposes, the implication of this argument is that the resulting
education and ownership might, in turn, lead to better health outcomes. This conjecture,
however, actually stands in direct contrast to much empirical research, which shows that
genomic information has no real impact on patients’ perceptions of control, information
seeking, or health behaviors.33
A way to create demand?
Every revolution needs the people’s support to succeed, and for personalized genomic
medicine, this means the allegiance of patients and health care consumers. One way this
need gets acknowledged by some proponents is through their concern to insure that the
public’s first impressions of personalized medicine are not negative. As one critic of
commercialized genomic medicine argues, “The unregulated and unvalidated introduction of
genomic self-testing may undermine physicians’ efforts to secure public confidence and
acceptance of this vital component in the emerging field of ‘personalized’ medicine.”34 But
the public’s role in the personalized medicine revolution has the potential to go much further
than passive acceptance. For many, the value of empowering patients is that it gives them a
stake in the movement itself, and it enlists them in helping the revolution succeed at both
clinical and public policy levels.
At the clinical level, the cause is advanced by patients who challenge their physicians to
adopt the tools and services of personalized genomic medicine. As one promotional
manifesto puts it:
Seventy million Baby Boomers, now or soon-to-be over age 60, seek to live not
just longer, but healthier and more productive lives. When they fully understand
and embrace personalized medicine, it will create an unprecedented level of
consumer demand. When physicians feel they may incur liability for not offering a
test that provides information on optimal care, the impetus toward adoption will be
even greater.35
At a policy level, personalized medicine’s proponents also need public help to ensure that
the health care system is structured to accommodate the approaches and needs of its
practice. Advocacy organizations like the Personalized Medicine Coalition and the National
Health Council use empowerment language to encourage public involvement on behalf of
legislation designed to facilitate personalized genomic medicine, like the Genomics and
Personalized Medicine Act (HR 5440).36 As one consumer advocate argues, “it is our
responsibility as patients to ensure the power of [personalized genomic medicine] is
leveraged for us each time we interact with the healthcare system.”37 Moreover, for the parts
of the health care system already committed to personalized medicine, a galvanized patient
population can also help to promote health care reimbursement and policies that advance the
movement’s interests.
The appeals to “patient empowerment” in the promotional literature for personalized
medicine show the importance of tracking emerging discourse about this “paradigm shift” if
we are to fully anticipate its social implications.38 We can see several forks in the road
ahead. First, since the virtue of patient empowerment ultimately has a weak grip on
personalized medicine’s pharmacogenomics side, it could easily be jettisoned when
decision-making falls into medicine’s traditional domains of authority, subverted as a device
for increasing patient compliance with medical recommendations, or simply exploited as a
campaign promise that serves only to garner public support and generate demand. For those
invested in employing patient empowerment as a facet of personalized medicine to serve as
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a moral stand against medical paternalism, anticipating and avoiding these outcomes will be
important.
The health benefits of much of personalized medicine’s genetic risk profiling side will
indeed depend on patient decision-making, but this fact turns out to have potentially
worrying implications of its own. For this side of the field, emphasizing patient
empowerment might unfairly inflate patient’s responsibilities for their health, either by tying
their empowered role to obligations to make decisions that conform to social expectations
and interests, by enlisting patients in quasi-contractual ways to help secure the success of the
personalized medicine paradigm through their decision-making, or by abandoning other
environmental, structural, and regulatory approaches to health promotion and risk reduction
in order to force the “choices” that individuals must make for themselves. The idea of
patient empowerment may run up against not only the limits of patients’ control over their
health, but also the limits of patient control over health care systems. For those committed to
preserving a more generous vision of health care as a social good, these dynamics are
important to anticipate and avoid as the practice of personalized genomic medicine moves
forward.
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